Varisha Zuhair

Varisha Zuhair

Auto-generated profile, based on publicly available information

Varisha Zuhair

Jinnah Sindh Medical University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in Health Science Reports
Verified
Journal Article
Open access
Abubakar NazirAbubakar Nazir
Abubakar Nazir
ANAwais Nazir
Awais Nazir
VZVarisha Zuhair
Varisha Zuhair
SAShafaq Aman
Shafaq Aman
SSSafi Ur Rehman Sadiq
Safi Ur Rehman Sadiq
DBDeusdedith Boniphace Bulimbe
Deusdedith Boniphace Bulimbe
Background and Aims: Antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by 2050 if left unaddressed, posing a severe threat to global health and modern medicine. This review analyzes the molecular and ecological mechanisms underlying antibiotic resistance and evaluates global efforts aimed at containment to identify actionable strategies to mitigate AMR's escalating impact. Methods: A systematic literature review was performed using databases including PubMed, ScienceDirect, Scopus, Google Scholar, and Web of Science, focusing on peer‐reviewed studies from 2000 to 2024. Search terms included “antibiotic resistance,” “resistance mechanisms,” “horizontal gene transfer,” and “AMR epidemiology.” A total of 152 articles were selected based on predefined inclusion criteria relevant to resistance mechanisms, epidemiological data, clinical outcomes, and public health interventions. Results: Findings underscore three dominant resistance pathways: target site modification, enzymatic degradation (e.g., β‐lactamases), and horizontal gene transfer via plasmids and transposons. Notably, resistance to last‐resort antibiotics (e.g., colistin, carbapenems) is rising in pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii , with treatment failure rates exceeding 50% in some regions. Surveillance gaps and unregulated antibiotic use, especially in LMICs, further accelerate resistance spread. Only a limited number of new antibiotic classes have been approved since 2010, underscoring the innovation gap. Conclusion: AMR is a quantifiable, escalating crisis that undermines decades of progress in infectious disease control. Tackling it requires coordinated action: strengthening antimicrobial stewardship, incentivizing antibiotic R&D, integrating environmental and clinical surveillance under One Health frameworks, and implementing global policy reforms. Without prompt action, AMR could surpass cancer in annual mortality by mid‐century.

29 June 2023 in New Microbes and New Infections
Verified
Journal Article
Open access
MOMalik Olatunde Oduoye
Malik Olatunde Oduoye
VZVarisha Zuhair
Varisha Zuhair
AMAndrew Marbell
Andrew Marbell
GOGbolahan Deji Olatunji
Gbolahan Deji Olatunji
AKAli Aamir Khan
Ali Aamir Khan
KKKarim Arif Karim
Karim Arif Karim

21 June 2024 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
AGAman Goyal
Aman Goyal
HJHritvik Jain
Hritvik Jain
MUMuhammad Usman
Muhammad Usman
VZVarisha Zuhair
Varisha Zuhair
SSSamia Aziz Sulaiman
Samia Aziz Sulaiman
SYShreyas Yakkali
Shreyas Yakkali
Aortic dissection (AD) is a catastrophic life-threatening cardiovascular emergency with a 1-2% per hour mortality rate post-diagnosis, characterized physiologically by the separation of aortic wall layers. AD initially presents as intense pain that can then radiate to the back, arms, neck or jaw along with neurological deficits like difficulty in speaking, and unilateral weakness in some patients. This spectrum of clinical features associated with AD is often confused with acute myocardial infarction, hence leading to a delay in AD diagnosis. Cardiac and vascular biomarkers are structural proteins and microRNAs circulating in the bloodstream that correlate to tissue damage and their levels become detectable even before symptom onset. Timely diagnosis of AD using biomarkers, in combination with advanced imaging diagnostics, will significantly improve prognosis by allowing earlier vascular interventions. This comprehensive review aims to investigate emerging biomarkers in the diagnosis of AD, as well as provide future directives for creating advanced diagnostic tools and imaging techniques.

23 April 2024 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
VZVarisha Zuhair
Varisha Zuhair
MMMuhammad Saqlain Mustafa
Muhammad Saqlain Mustafa
MSMuhammad Ashir Shafique
Muhammad Ashir Shafique
BRBurhanuddin Sohail Rangwala
Burhanuddin Sohail Rangwala
ASAreej Shakil
Areej Shakil
MOMuhammad Ishtiaq Obaid
Muhammad Ishtiaq Obaid

1 January 2024 in Clinical Medicine Insights: Endocrinology and Diabetes
Verified
Journal Article
Open access
VZVarisha Zuhair
Varisha Zuhair
ASAreeba Tufail Sheikh
Areeba Tufail Sheikh
NSNimra Shafi
Nimra Shafi
ABAreesha Babar
Areesha Babar
AKAreeb Khan
Areeb Khan
EAEman Ali
Eman Ali
Objective: The main objective was to assess the therapeutic efficacy of selenium alone versus a combination of myo-inositol and selenium (MI + Se) in treating patients with autoimmune thyroiditis (AIT). The study aims to determine which treatment option is more effective in restoring euthyroid state, as indicated by changes in thyroid-stimulating hormone (TSH), T3, T4, thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb) Methods: Google Scholar and PubMed databases were searched for randomized controlled trials (RCTs) and observational studies that reported outcomes of combined treatment (MI + Se) in restoring a euthyroid state, specifically comparing it with selenium-only (Se-only) treatment. Changes in TSH, T3, T4, TPOAb, and TgAb levels from baseline were defined as indicators to compare the effect of combined versus selenium-only treatment in restoring euthyroid levels. The Cochrane risk of bias tool and Newcastle Ottawa Scale were used to assess the quality of the randomized control trials included in the study. Review Manager (version 5.4, Nordic Cochrane Centre, Copenhagen, Denmark) was used for statistical analysis. Result: We pooled three studies, enrolling 151 participants in the MI + Se group and 137 participants in the Se group. Supplementation of Se with MI demonstrated a significant reduction in TSH levels compared to Se alone (SMD = −1.15, 95% CI: −1.60 to −0.69, P < .00001). MI + Se treatment also significantly reduced TgAb levels compared to Se (SMD = −0.51, 95% CI: −0.78 to −0.24, P = .0002). In contrast, TPOAB, T3 and T4 levels were non-significantly reduced from baseline in patients treated with MI + Se when compared to Se alone (SMD = −0.81, 95% CI: −0.44 to 0.09, P = .20), (SMD = 0.16, 95% CI: −0.09 to 0.42, P = .22), and (SMD = 0.30, 95% CI: −0.23 to 0.83, P = .26) respectively. Conclusion: Supplementation of Se with MI showed a significant reduction in TSH and TgAb levels compared to selenium-only treatment, with a non-significant reduction in TPOAB, T3, and T4 levels. This entails the need for powered clinical trials and observational studies with longer follow-ups to critically assess the role of combined therapy in restoring euthyroid state in patients with AIT.

28 November 2023 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
ABAreesha Babar
Areesha Babar
RARabbiya Ali
Rabbiya Ali
VZVarisha Zuhair
Varisha Zuhair
Dear editor, The Glucagon-like-peptide receptor- 1, agonists belong to a class of drugs that have been used to treat type 2 diabetes. Liraglutide and Semaglutide are drugs of this class, commonly sold under the brand names Saxenda and Wegovy respectively. These drugs have also been approved by the FDA for weight loss in diabetic and non-diabetic obese people.1 The mechanism of action of GLP-1 agonists involve stimulating insulin secretion and delaying gastric emptying. Moreover, GLP-1 receptors are found on adipose tissue, where they promote the conversion of stored fat into energy. They also target the appetite center in the hypothalamus which increases satiety and reduces food intake to cause weight loss. A large number of females who struggle with obesity, concomitantly suffer from Polycystic Ovarian syndrome (PCOS) also which is a multifactorial endocrine disorder in women of reproductive age, affecting 4-20% women around the world.2 One of the major manifestations of this syndrome is weight gain and difficulty in losing it. In contemporary medicine, the treatment of PCOS is limited to lifestyle intervention and symptomatic management. Thus, the patients of PCOS are often told by their doctors to simply lose weight. Physicians around the world agree that weight loss is crucial for women with PCOS who are obese to attain better metabolic, reproductive, and cardiovascular outcomes, because if not treated, obesity worsens the presentation of PCOS. But it is noteworthy that the ongoing hormonal imbalances, increased appetite and insulin resistance in this syndrome, all work against the body’s natural mechanism to lose weight and make it extremely difficult for the patient. This creates a dire need for external interventions regarding weight management in PCOS. Where conventional methods like dietary modifications and exercise alone do not provide substantial results, GLP-1 agonists can be a breakthrough for the management of PCOS since recent research and clinical data also provides evidence of correlation between obesity, GLP-1 kinetic alterations, and pathophysiology of PCOS.3 Hence the use of GLP-1 agonists can be a viable option for treatment of PCOS as multiple clinical trials have shown significant weight reduction, decrease in testosterone levels, improvement in insulin sensitivity and menstrual cycles.4 As the prevalence of PCOS continues to rise in Pakistan, the major presenting complaints include; weight gain, facial hair, acne and menstrual irregularities in teenage girls and infertility in married females. ---Continue